<DOC>
	<DOCNO>NCT01412424</DOCNO>
	<brief_summary>MYCAPSSA™ ( formerly Octreolin™ ) proprietary oral form approve injectable medical product octreotide use treat acromegaly . This study evaluate efficacy safety MYCAPSSA™ treatment patient acromegaly .</brief_summary>
	<brief_title>Efficacy Safety Octreotide ( MYCAPSSA™ Formerly Octreolin™ ) Acromegaly</brief_title>
	<detailed_description>The study consist 2 period , Core Treatment Period 7 month optional Extension Treatment Period 6 month , total study duration 13 month . The Core Treatment Period consist 2 phase , Dose Escalation Phase least 2 month identify therapeutic dose study participant Fixed Dose Phase 2 5 month therapeutic dose maintain . Participants eligible enter Fixed Dose Phase Core Treatment Period clinically biochemically control . The criterion use allow entry voluntary 6-month Extension Treatment Period . The Core Treatment Period study complete participant least 2 month treatment Fixed Dose Phase total treatment duration least 7 month . Participants elect continue Extension Treatment Period maintain therapeutic dose period . At end study ( last dose MYCAPSSA either Core Treatment Period Extension Treatment Period ) , 2-week follow-up period safety assessment .</detailed_description>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Adult subject , age 18 75 year old , inclusive . Subjects acromegaly define documented evidence growth hormonesecreting pituitary tumor abnormally responsive glucose , document elevate insulinlike growth factor1 ( IGF1 ) , currently receive stable dose somatostatin analog least previous 3 month . A serum IGF1 level &lt; 1.3 x upper limit normal ( ULN ) serum growth hormone ( GH ) level &lt; 2.5 ng/mL . Subjects able willing comply requirement protocol . Subjects able swallow capsule . Subjects able understand sign write informed consent participate study . Receiving regular injection somatostatin analog less frequently month , ie , long every 4 week . Symptomatic cholelithiasis . Received pituitary radiotherapy within ten year prior screen . Undergone pituitary surgery within prior 6 month . Any condition may jeopardize study participation . Clinically significant gastrointestinal ( GI ) , renal , hepatic disease determine Investigator . Conditions ( eg , bariatric surgery ) significantly affect gastric acidity empty . Current use ( within 1 month ) proton pump inhibitor ( PPIs ) current chronic use H2antagonists . Female patient pregnant lactate . Current recent ( &lt; 3 month ) therapy pegvisomant . Current recent ( &lt; 2 month ) therapy cabergoline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>acromegaly</keyword>
	<keyword>IGF-1</keyword>
	<keyword>growth hormone</keyword>
	<keyword>Octreolin</keyword>
	<keyword>octreotide</keyword>
	<keyword>somatostatin analog</keyword>
</DOC>